1 active not recruiting, 1 terminated, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow RP3: new trials by email Literature Review of RP3 trials Research Report on RP3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel - Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Withdrawn | Replimune, Inc. | 2024-01-30 | 2025-03-11 | |
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC RP2, RP3, atezolizumab - Refractory Metastatic Colorectal Cancer, pMMR | Phase 2 | Terminated | Replimune, Inc. | 5 | 2023-06-29 | 2026-02-02 |
| Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours RP3, Nivolumab - Advanced Solid Tumor | Phase 1 | Active not recruiting | Replimune, Inc. | 123 | 2020-12-29 | 2026-02-27 |
Colorectal Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Replimune, Inc. (3)
United States (3) · France (2) · Greece (2) · Spain (2) · United Kingdom (2) · Czechia (1) · Germany (1) · Poland (1)
Gary Vanasse, MD (2) · David Cohan, MD/FACS (1)